About Bluebird Bio (BLUE)

Bluebird Bio Inc (BLUE) is a biotechnology company focused on developing transformative gene therapies for severe genetic diseases. The company's primary focus is on diseases that are caused by a single missing or defective gene, with the aim of providing patients with long-lasting and potentially curative treatments. BLUE's lead product candidate is called LentiGlobin, which is being developed for the treatment of severe genetic blood disorders such as beta-thalassemia and sickle cell disease. The company is also developing other product candidates, including therapies for cerebral adrenoleukodystrophy, a rare genetic disorder affecting the nervous system, and for multiple myeloma, a type of blood cancer.

BLUE's stock price history has seen significant volatility over the past few years. In 2015, the company's stock surged as high as $196.50 per share, fueled by optimism surrounding its gene therapy platform. However, the stock experienced a sharp decline in 2016, due in part to safety concerns and regulatory setbacks. Since then, BLUE's stock price has shown some recovery, but it still has not reached its previous highs. As of [date], the stock is trading at approximately $[price] per share.